PharmaBoardroom Releases The Netherlands Pharmaceuticals Report
Pharmaboardroom releases its new 62 page Netherlands Healthcare and Life Sciences Report 2016.
This report offers companies, investors, policymakers, and stakeholders crucial insight into a country at the global forefront of healthcare, pharmaceutical and biotechnological innovation
The report features an exclusive in-depth interview with Europe’s longest-standing Minister of Health, Edith Schippers, as well as with leading figures from both public institutions and private companies. Also included are up-to-date facts and figures on The Netherlands’ healthcare and pharma sectors.
This report is an authoritative assessment of one of the Dutch healthcare and pharma markets. The Netherlands is leading the way globally in:
Sustainable and efficient healthcare
The Dutch government has championed increasing transparency, empowering the patient, developing home care, modernizing hospital IT, and fostering EU-wide collaboration to further boost the Dutch healthcare system’s reputation as one of the best in the world.
Local affiliates are firmly committed to collaboration with regulators while the industry itself is locally implementing experimental market access models.
The Dutch biotech scene is booming both in terms of Nasdaq IPOs and in prestigious partnerships with big pharma MNCs. This propels the local value chain and strengthens the Netherlands’ innovative reputation.
The density of the Netherlands’ life sciences community is helping to bring together start-ups, MNCs, service providers, and academic institutions. The pharmaceutical, digital, and medtech worlds are colliding in a variety of specialized clusters; propelling innovative ideas and practices.
The Netherlands Healthcare and Life Sciences Report 2016 includes an in-depth cover story, “Innovation with Collaboration” which covers:
- Healthcare priorities for the Dutch presidency of the EU
- Process Innovation
- Service Providers
The report also includes interviews with:
- Edith Schippers, Minister of Health
- Yvonne van Rooy, Dutch Hospital Association (NVZ)
- Peter Schoevers, Julius Clinical
- Ad Schuurman, National Health Care Institute
- Onno van de Stolpe, Galapagos
- Anna van Poucke, KPMG Healthcare
- Hans Hofstraat, Philips Research
- Bart Vanhauwere, Roche Netherlands
- “The private sector is also of utmost importance to ensure innovation, cost-effectiveness, and flexibility.” Edith Schippers, Minister of Health
- “Patient education will become an important area of activity for all healthcare stakeholders, in order for the patient to fulfil his role as a true partner to the care process” Yvonne van Rooy, Dutch Hospital Association (NVZ)
- “An organization that could ally the academic strength and credibility of an ARO with the operational capabilities of a CRO would have a very promising potentital” Peter Schoevers, Julius Clinical
- “From a long-term perspective, a multiple-EU states approach is the best guarantee to improving patient access” Ad Schuurman, National Health Care Institute
- “We are not there yet, but in ten years time we could be an independent specialty pharma company. That’s very much the objective” Onno van de Stolpe, Galapagos